CCCC — C4 Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $123.55m
- -$121.35m
- $35.58m
Annual cashflow statement for C4 Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -66.3 | -83.9 | -128 | -132 | -105 |
| Depreciation | |||||
| Non-Cash Items | 10.6 | 25.5 | 37.3 | 30.7 | 30.7 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -13.2 | -30.1 | -16.8 | -6.94 | 7.65 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -67.2 | -87 | -106 | -107 | -65.2 |
| Capital Expenditures | -0.65 | -1.28 | -5.5 | -1.71 | -0.18 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -190 | -188 | 63.9 | 160 | -51.1 |
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -191 | -189 | 58.4 | 158 | -51.3 |
| Financing Cash Flow Items | — | 169 | 0.37 | 0.368 | 0.382 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 349 | 171 | 1.15 | 45.5 | 45.3 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 91.2 | -105 | -46.4 | 97 | -71.1 |